Taiwan To Double Stockpile Of Tamiflu, Relax Regs For Flu Drugs
This article was originally published in PharmAsia News
Executive Summary
Taiwan health authorities decided to increase the nation's supply of Roche's Tamiflu (oseltamivir) - enough to treat 7 million against the H1N1 flu virus. A stockpile that size would be enough to treat about 30 percent of Taiwan's population, beyond the current supply able to treat 14 percent. The flu-prevention task force also decided to relax some regulations to allow expanded use of the antiviral as the peak season for the flu neared Taiwan. The country also has a stockpile of shikimic acid, the active pharmaceutical ingredient in Tamiflu, enough to cover 4 percent. (Click here for more
You may also be interested in...
Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time
Small sterilizers told Medtech Insight that they were ready for the EPA’s controversial EtO emissions rule, while community advocates expressed concerns.
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.